The price of Viking Therapeutics Inc (NASDAQ:VKTX) shares last traded on Wall Street rose 28.31% to $64.68.
VKTX stock price is now 13.45% away from the 50-day moving average and 51.60% away from the 200-day moving average. The market capitalization of the company currently stands at $7.13B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $105, Morgan Stanley recently initiated with Overweight rating for Viking Therapeutics Inc (NASDAQ: VKTX). On May 16, 2024, Raymond James Upgraded its previous ‘Outperform’ rating to ‘Strong Buy’ on the stock increasing its target price from $115 to quote $116, while ‘Oppenheimer’ rates the stock as ‘Outperform’
In other news, ZANTE GREG, Chief Financial Officer sold 66,756 shares of the company’s stock on May 03 ’24. The stock was sold for $4,986,008 at an average price of $74.69. Upon completion of the transaction, the Chief Financial Officer now directly owns 174,854 shares in the company, valued at $11.31 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 01 ’24, Chief Operating Officer Mancini Marianna sold 281,425 shares of the business’s stock. A total of $22,136,474 was realized by selling the stock at an average price of $78.66. This leaves the insider owning 348,508 shares of the company worth $22.54 million. A total of 7.05% of the company’s stock is owned by insiders.
During the past 12 months, Viking Therapeutics Inc has had a low of $8.28 and a high of $99.41. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 37.69, and a quick ratio of 37.69. The fifty day moving average price for VKTX is $56.8593 and a two-hundred day moving average price translates $42.928425 for the stock.
The latest earnings results from Viking Therapeutics Inc (NASDAQ: VKTX) was released for 2024-06-30.
